Background Medial opening wedge high tibial osteotomy (HTO)
complications in the immediate postoperative period, blood transfusions, or symptomatic deep vein thrombosis? Methods Between January 2015 and May 2017, a single surgeon performed 156 HTOs, all of which were done using the medial opening wedge technique. We began using intravenous TXA for all HTOs in June 2016. This left us with 89 patients who were treated during a time when no TXA was used and 67 patients who were treated when all patients received TXA. Two patients in the control group had simultaneous TKA in the contralateral leg and one patient in each group had missing data so these patients were excluded, leaving 86 (97%) patients in the control group and 66 (98.5%) in the TXA group available for analysis in this retrospective study. There were no demographic differences between the groups in terms of age, sex, body mass index, and baseline hemoglobin values. Total estimated blood loss was the primary outcome variable, which was calculated using total blood volume and decrease in hemoglobin values. Secondary outcome variables included pain VAS at rest the day after surgery, wound complications in the immediate postoperative period, allogeneic blood transfusions, and occurrence of symptomatic thromboembolic manifestations. The decision on when to transfuse was based on predetermined criteria. An orthopaedic surgeon not involved in patient care collected the patient data from electronic medical records and did chart review. Results The TXA group had less total blood loss (372 6 36 mL versus 635 6 53 mL, mean difference 263 mL [95% confidence interval, 248-278]; p < 0.001). Between groups, differences in VAS pain scores at rest the day after surgery favored the TXA group but were small and unlikely to be clinically important. There were two wound complications in the control group (one hematoma and one superficial Each author certifies that neither he or she, nor any member of his or her immediate family, has funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research® neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA approval status, of any drug or device before clinical use. Each author certifies that his or her institution approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.
Introduction
Medial opening wedge high tibial osteotomy (HTO) is an established treatment for medial compartment knee osteoarthritis with varus deformity. The procedure is intended to shift the mechanical axis from medial to slightly lateral to the midline of the knee to minimize the load and subsequently delay osteoarthritis progression [2] . The incidence of HTO is increasing, and interest in HTO as an adjunctive procedure is growing steadily as a result of technical advances in cartilage healing procedures and meniscal transplantation for which malalignment would otherwise represent a contraindication [17] . Osteotomy at the metaphyseal level, and the associated extensive soft tissue release, may cause intra-and postoperative bleeding. After HTO, the periosteum cannot be approximated or closed over the osteotomy site and the plate; only the subcutaneous tissue and skin contain postoperative bleeding and potential hematoma. This paucity of soft tissue coverage around the proximal medial tibial surface creates an anatomic disadvantage that may lead to soft tissue complications such as wound hematoma, impaired wound healing, and superficial skin infections. Various authors have reported that between 5% and 7% of patients experience wound complications after HTO [3, 11, 20] . Reduced postoperative bleeding after HTO should theoretically result in less hematoma and better wound healing, which, in turn, should reduce pain and facilitate early rehabilitation [15] .
Tranexamic acid (TXA) inhibits fibrinolysis and competitively inhibits the conversion of plasminogen to plasmin (which cleaves the fibrin into fibrin degradation products, allowing clots to dissolve) [1] . The role of TXA in blood conservation is well documented across surgical specialties, including orthopaedics, cardiology, neurosurgery, craniofacial, and obstetrics and gynecology [5] .
However, the clinical value of TXA in HTO has not been investigated extensively. To the best of our knowledge, the only available study on this topic is from Suh et al. [18] , who found topical TXA effective in reducing postoperative blood loss after medial opening wedge HTO in a retrospective analysis of a small number of patients. No prior study has determined the efficacy of intravenous (IV) TXA in HTO. Furthermore, the effects of TXA on total estimated blood loss, incidence of wound complications, symptomatic thromboembolic events, and early pain scores in HTO have, to our knowledge, not been studied.
We therefore compared patients who underwent HTO and asked: (1) Does IV TXA reduce total estimated blood loss in HTO? (2) Does TXA use in HTO affect in-hospital endpoints as measured by visual analog scale (VAS) pain scores at rest the day after surgery, wound complications during the immediate postoperative period, blood transfusions, or symptomatic deep vein thrombosis (DVT)?
Patients and Methods
At our institution, we began to routinely administer IV TXA to all patients undergoing HTO in June 2016. The consecutive series of all patients immediately before and after the initiation of routine use of TXA through May 2017 were reviewed and institutional review board approval was obtained. Data were collected from the patients' electronic medical records.
Patients were included if they had undergone medial opening wedge HTO performed as an individual procedure for symptomatic medial compartment degenerative osteoarthritis, had > 5°varus alignment on standing knee AP radiographs, and were between the ages of 20 and 69 years. Patients were excluded if they had instability or lateral compartment disease; had incomplete data for the endpoints studied, including a lack of postoperative hemoglobin values, incomplete Hemovac drain output data as a result of early drain pullout, and other missing data in patient records; had concomitant arthroscopic procedures or underwent HTO for indications other than osteoarthritis; underwent other surgical procedures performed in the involved or contralateral leg; or had known bleeding disorders.
From January 2015 to May 2017, 156 medial opening wedge HTOs were performed; two patients were excluded from the pre-TXA group because they underwent a simultaneous TKA on their contralateral knee. Two additional patients (one in each group) were excluded based on incomplete data from drain pullout on the day of the surgery. Of the remaining 152 patients, 66 (seven men and 59 women) received IV TXA, forming the TXA group, and 86 (nine men and 77 women) not administered TXA comprised the control group (Fig. 1 ).
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Perioperative Management and Surgical Procedure
All patients were managed by a similar perioperative protocol. A systematic medical clearance protocol was implemented to identify patients with anemia and other medical comorbidities and prepare them for surgery. We recorded preoperative comorbidities that were thought to influence either bleeding or thromboembolic tendency. Similarly, we documented the use of anticoagulants such as warfarin and clopidogrel; none of the patients in this study were on any anticoagulant drugs before surgery. The same surgeon (TKK), a knee surgery specialist, performed all HTOs. The degree of correction, length of the osteotomy, and approximate length of screws were templated preoperatively. All patients received spinal anesthesia with a goal mean arterial pressure of 60 to 70 mmHg and femoral nerve block with a catheter was maintained for postoperative pain management. A pneumatic tourniquet was used in all patients and was inflated to 100 to 120 mmHg higher than the systolic blood pressure. An approximately 6-cm longitudinal skin incision was made between the posteromedial border of the tibia and the medial aspect of the tibial tuberosity. Plate positioning and osteotomy site (approximately 4 cm distal to the medial joint line) were provisionally marked at this step. The superficial medial collateral ligament and pes anserinus were subperiosteally released from the tibia. A radiolucent Hohmann retractor was then inserted behind the posterior surface of the tibia to protect the neurovascular structures and expose the osteotomy site. Two Kirschner wires were inserted sequentially, anteriorly, and posteriorly at the osteotomy level and were directed to the safe zone between the level of the tip of the fibular head and the circumference line of the fibula head under fluoroscopic guidance.
The osteotomy was performed beneath the Kirschner wires using an oscillating saw until the osteotomy line extended within 10 mm medial to the lateral cortex of the tibia. Then the surgeon performed a biplanar osteotomy extending the osteotomy beneath the tibial tuberosity. Thin osteotomes were used to open the osteotomy followed by a calibrated osteotome to achieve a predetermined correction. After the desired degree of correction was confirmed with navigation (OrthoPilot ® ; Aesculap, Tuttlingen, Germany), the osteotomy site was held in position with a laminar spreader, and the locking plate (Tomofix; DePuy Synthes, West Chester, PA, USA) was fixed in position. After the locking screws were applied, the resultant defect was filled using synthetic bone graft (Cancellous Coarse; Community Tissue Services, Dayton, OH, USA). The tourniquet was deflated after osteotomy and plate fixation to cauterize bleeding vessels and restore hemostasis. A suction drain was placed subcutaneously, and wound closure was done without undue skin tension. A compression dressing was applied and a long knee brace with a CryoCuff ® (Howmedicare, Seoul, Korea) was worn for support.
The patients began performing isometric quadriceps and straight leg raise exercises on the first postoperative day. Patients were allowed knee ROM exercises as pain tolerated; they started passive movement with a continuous passive motion machine on the second postoperative day. Patients were kept nonweightbearing, walking with crutch ambulation initially followed by partial weightbearing of 25% to 50% of their body weight until there was evidence of radiologic healing of the osteotomy site. Surgical technique, pain management, and rehabilitation protocols did not change during the study.
Tranexamic Acid Protocol
Two grams of TXA (500 mg/5-mL ampules; Shin Poong, Seoul, South Korea) were infused IV 10 minutes before tourniquet application, and the same amount was repeated 3 hours after the initial dose. Intravenous cefazolin (2 g) was administered for antibiotic prophylaxis.
Anticoagulation Protocol
All anticoagulant drugs were stopped before surgery, and the coagulation profile (platelet count, prothrombin time, activated plasma thromboplastin time, and international normalized ratio) was repeated and ensured to be normal on admission. All patients before and after the routine use of TXA at our institution were treated with the same venous thromboembolism prophylaxis protocol, which consisted of bilateral intermittent pneumatic compression during the hospital stay and 100 mg aspirin once a day for 6 weeks.
Postoperative Data Collection
The primary study endpoint was total estimated blood loss. We calculated this by a formula described in previous studies [7, 10] , which was based on the patient's total blood volume and hemoglobin loss after surgery. Blood volume (BV) was estimated according to the method of Nadler et al. [12] Total blood loss is calculated from total hemoglobin loss (Hbloss), which in turn is calculated from the difference between preoperative Hb and the minimum Hb during the hospital stay (postoperative day 2 in our case):
Blood loss (in mL) = 100 mL/dL x Hbloss/Hbi Hbloss = BV x (Hbi -Hbe) x 10 dL/L + Hbt Hbi = Hb concentration before surgery (g/dL) Hbe = Hb concentration during hospital stay (g/dL) Hbt = Total amount of allogeneic Hb transfused (g). Because there were no transfusions, this variable was dropped from the equation in our study.
The postoperative Hemovac (Barovac; Sewoon Medical Co Ltd, Cheonan, Korea) drainage volume at 24, 48, and 72 hours was noted. The suction drain was removed after 72 hours in most patients; however, three patients in the control group and four patients in the TXA group had their drains removed on the second postoperative day because their drain amount was minimal to none and they desired earlier discharge. We evaluated preoperative and postoperative Hb/hematocrit (values were obtained during the second postoperative day) for both groups. To calculate the postoperative decrease in Hb, we subtracted this postoperative day 2 Hb level from the preoperative Hb level.
Secondary outcome variables included VAS pain at rest the day after surgery, wound complications during the immediate postoperative period, blood transfusions, and symptomatic thromboembolic events. The VAS was used to evaluate pain in the operative site postoperatively. The nurse on duty documented the postoperative day 1 pain VAS scores with the patient at rest. Wound status was documented daily. Oozing from the wound persisting beyond 2 days after surgery, bullae formation, subcutaneous hematoma that needed aspiration or surgical drainage, and wound infections that required additional treatments such as antibiotic coverage or surgical débridement were recorded.
We collected data on perioperative blood transfusion. We followed the same blood transfusion criteria throughout the course of the study. Allogeneic blood transfusion was given postoperatively if the Hb fell below 7 g/dL and no blood transfusions were given if the Hb level was > 8 g/dL. Patients with a Hb of 7 to 8 mg/dL received blood transfusions based on the presence of anemic symptoms such as dyspnea or tachycardia, which persisted even after volume replacement. We did not perform routine DVT screening. However, all the patients were available for review and the data from outpatient records were checked until their last followup visit for any occurrence of symptomatic thromboembolic manifestations.
All data were obtained by chart review performed by an individual not involved in the direct care of these patients (KHM).
Demographics
When we evaluated the demographic data, we found no differences between the groups ( Table 1 ). The average patient age was 57 years (range, 28-49 years) with no difference between groups (57 versus 58 years, p = 0.714). The average body mass index was 26 kg/m 2 (range, 21-40 kg/m 2 ) with no difference between the groups (26 versus 27 kg/m 2 , p = 0.396). The patient population was predominantly women (89%); 11% of the patients were men (nine of 86 in the control group and seven of 66 in the TXA group; p = 0.362). Similarly, no difference existed between the baseline preoperative hemoglobin values between the two groups (13.5 versus 13.2 g/dL; p = 0.572).
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Statistical Analyses
The statistical analysis was performed using SPSS software (version 22.0; Chicago, IL, USA). We used the chi-square test to compare and analyze categorical data. The Student's t-test was used to compare continuous variable outcome measures (which were presented as mean 6 SD) between the two groups. Results were considered statistically significant if the p value was < 0.05. A post hoc power analysis was performed using the effect size of total estimated blood loss (263 mL) with a common SD of 53 mL. On considering a = 0.05 and sample size = 150, the calculated power is more than 0.95.
Results
The total estimated blood loss was lower in the TXA group than in the control group (372 6 36 mL versus 635 6 53 mL, respectively; mean difference 263 mL [95% confidence interval {CI}, 248-278]; p < 0.001; Table 2 ). The patients in the TXA group also had less postoperative Hemovac drainage and a smaller Hb/hematocrit decrease. Interestingly, the decrease in drain output was more marked on postoperative day 1 than on subsequent postoperative days. Drain output on postoperative day 1 in the TXA group was 92.6 mL, whereas it was 255 mL in the control group (p < 0.001). The drain volume on postoperative days 2 and 3 did not show a large difference between the two groups (278 mL in the TXA group and 280 mL in the control group). Between-group differences in VAS pain scores at rest the day after surgery favored the TXA group, but were small and unlikely to be clinically important (3.2 6 0.3 in the TXA group versus 4.6 6 0.5 in the control group, mean difference 1.4 [95% CI, 1.26-1.54]; p < 0.001). With the numbers available, there were no differences in the proportion of patients with wound complications in each group. None of the patients in the TXA group had wound complications. In the control group, one patient had a superficial wound infection in the immediate postoperative period, which was treated with meticulous wound care and IV antibiotics. One patient had a tense wound hematoma, which was treated by surgical drainage. No patient in either group received a blood transfusion and no patient in either group had an asymptomatic thromboembolic event.
Discussion
The prophylactic administration of TXA seems to be well established for routine use in lower extremity arthroplasty to minimize surgical blood loss [1, 4, 9] . However, to the best of our knowledge, there is only one other study [18] on the use of TXA in HTO and that was limited to some extent by a small sample size. The need for determining the efficacy of TXA in HTO is paramount, because the bleeding after HTO can result in local wound complications, 2 )* 26 6 2 2 7 6 2 0.396 Baseline Hb (g/dL)* 13 6 0.4 13 6 0.5 0.572 *Mean 6 SD; TXA = tranexamic acid; BMI = body mass index; Hb = hemoglobin. Values are mean 6 SD; TXA = tranexamic acid; Hb = hemoglobin.
increased pain, and need for blood transfusion. The purpose of this study was to evaluate the effectiveness of IV TXA in HTO in terms of total estimated blood loss. Although we found substantially less total estimated blood loss after HTO among patients who received IV TXA, there were no transfusions in either group, and although our study was fairly large, it was not large enough to perform statistical comparisons on rare endpoints like wound complications and occurrence of symptomatic DVT. For that reason, we cannot make a recommendation about whether TXA should be used routinely in patients undergoing HTO. The study has several limitations. First, it was a retrospective study. Patients were not randomized, and so selection bias was a concern; we mitigated this by evaluating a consecutive series of patients treated before and after we began using TXA routinely, and so the treatment groups seemed quite comparable. The other elements of care were similar in this single-surgeon series. To limit assessment bias, an orthopaedic surgeon (KHM) not involved in patient treatment evaluated the pre-and postoperative medical records. Second, the followup evaluation did not assess long-term differences in pain VAS scores or functional outcomes such as improvement in knee pain; however, to our knowledge, studies have not suggested that TXA influences those endpoints in any meaningful way. Third, there is a possibility of chronologic bias in terms of improved surgeon experience over the course of the study leading to lesser blood loss in the TXA group; however, our operative times in both groups were quite similar. Fourth, our study is underpowered on endpoints related to the safety profile of TXA. None of the patients in the TXA group had symptomatic thromboembolic events; moreover, we did not perform routine DVT screening and our sample size is too small to claim that the treatment is safe. Finally, the patients in this series were generally healthy and active as one would expect in patients undergoing HTO and results could be different in populations of patients in whom chronic diseases are more prevalent.
We found that IV TXA reduced calculated total estimated blood loss among patients undergoing HTO. In a smaller study, Suh et al. [18] recently demonstrated the efficacy of topical TXA in HTO in a retrospective study in which they compared 15 patients who received TXA with 15 patients in a control group. Two grams of TXA in 20 mL normal saline was administered into the operative site through the drain immediately after wound closure. They noted a reduction in the total drain collection in the TXA group compared with the control group. The Hb decrement on postoperative day 1 was minimal in the TXA group when compared with the control group. We preferred IV administration over the topical route in our study because topical administration may cause drug seepage into tissue spaces and swelling that poses a theoretical risk of jeopardizing wound integrity. The IV route, on the other hand, acts systemically and eliminates these risks. Topical administration is effective in TKA because the intraarticular injection of TXA after tight capsular closure ensures the intraarticular containment of the drug, which will have a tamponade effect on bleeding. The same effect would not be expected in HTO because the drug is not contained in the operative site. Tranexamic acid has been found to reduce bone bleeding in other extraarticular appendicular sites such as the acetabulum and calcaneum. Intravenous TXA (1 g IV before skin incision plus 1 g IV at the time of wound closure) reduced total estimated blood loss and the transfusion rate in patients undergoing periacetabular osteotomy [19] . In a randomized controlled trial, Xie et al. [21] demonstrated that the administration of TXA reduces postoperative drain volume on postoperative day 1 and wound complications in calcaneal fracture fixation, another anatomic region that has a propensity for wound complications. Similarly, in the present study, the difference in drain output between the two groups was substantial on postoperative day 1 (92.6 6 28 mL in the TXA group versus 255 6 68 mL in the control group) compared with subsequent postoperative days (278 6 48 mL in the TXA group and 280 6 105 mL in the control group). The difference in drain volume can be explained by the fact that therapeutic plasma concentration of TXA is 10 hours from the time of administration [14] .
In addition to decreasing total estimated blood loss, TXA seems to be associated with less postoperative pain in total joint arthroplasties [8, 13] . In our study, VAS pain scores were lower in the TXA group than the control group, possibly as a result of minimal bleeding and blood collection at the operative site. This statistical difference, however, may not be clinically relevant and thus it remains unclear if TXA administration will result in less pain for patients who undergo HTO.
In our study there were two wound complications in the control group and none in the TXA group. With the numbers available, we found no differences in wound complications, transfusions, or symptomatic thromboembolic events. Wound-related complications such as hematoma, delayed wound healing, and superficial skin infections constitute approximately 4% to 5% of complications after medial opening wedge HTO [16, 17, 20] . The effect of TXA in minimizing wound complications after HTO has not been studied. Generally, measures to avoid skin complications include choosing the proper skin incision, appropriate soft tissue handling, meticulous hemostasis, wound closure without excess tension, and regular postoperative care. During HTO, the plate is placed in the subcutaneous plane and covered only by a very thin layer of fascia and skin. Overt postoperative blood collection or hematoma resulting from oozing at the osteotomy site may jeopardize wound healing. Although our Volume 476, Number 11 Tranexamic Acid in High Tibial Osteotomy 2153 study was the largest study on TXA in patients undergoing HTO of which we are aware, it is still far too small to detect differences in these kinds of uncommon complications. Because no transfusions were administered in either group, we cannot make a strong claim in favor of routine use of TXA, because the importance of the reduced calculated estimated blood loss was not supported by a reduction in transfusion use. None of the patients in our study had symptomatic DVT and several studies have tended to establish the safety profile of TXA [4, 6, 9] . This study demonstrates that the systemic administration of TXA reduces postoperative blood loss in medial opening wedge HTO; however, insofar as no transfusions were administered to patients even before the routine use of TXA in this series, and no clinically important difference in pain scores was identified, the clinical benefit of routine use of TXA in patients undergoing HTO remains uncertain. Our study was too small to make safety-related claims on rare endpoints such as wound complications or thromboembolic events. Larger, and preferably randomized, trials are needed to help define whether it is important to use TXA in this setting. Our data can help inform sample size calculations for such studies.
